301 related articles for article (PubMed ID: 17706004)
1. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial.
Chapple C; DuBeau C; Ebinger U; Rekeda L; Viegas A
Curr Med Res Opin; 2007 Oct; 23(10):2347-58. PubMed ID: 17706004
[TBL] [Abstract][Full Text] [Related]
2. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist.
Steers W; Corcos J; Foote J; Kralidis G
BJU Int; 2005 Mar; 95(4):580-6. PubMed ID: 15705084
[TBL] [Abstract][Full Text] [Related]
3. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
Haab F; Stewart L; Dwyer P
Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
[TBL] [Abstract][Full Text] [Related]
4. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.
Foote J; Glavind K; Kralidis G; Wyndaele JJ
Eur Urol; 2005 Sep; 48(3):471-7. PubMed ID: 15990219
[TBL] [Abstract][Full Text] [Related]
5. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study.
Haab F; Corcos J; Siami P; Glavind K; Dwyer P; Steel M; Kawakami F; Lheritier K; Steers WD
BJU Int; 2006 Nov; 98(5):1025-32. PubMed ID: 16879437
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of health-related quality of life outcomes with darifenacin.
Abrams P; Kelleher C; Huels J; Quebe-Fehling E; Omar MA; Steel M
BJU Int; 2008 Jul; 102(2):208-13. PubMed ID: 18325056
[TBL] [Abstract][Full Text] [Related]
8. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.
Chapple C; Steers W; Norton P; Millard R; Kralidis G; Glavind K; Abrams P
BJU Int; 2005 May; 95(7):993-1001. PubMed ID: 15839920
[TBL] [Abstract][Full Text] [Related]
9. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB.
Zinner N; Susset J; Gittelman M; Arguinzoniz M; Rekeda L; Haab F
Int J Clin Pract; 2006 Jan; 60(1):119-26. PubMed ID: 16409440
[TBL] [Abstract][Full Text] [Related]
12. Increased warning time with darifenacin: a new concept in the management of urinary urgency.
Cardozo L; Dixon A
J Urol; 2005 Apr; 173(4):1214-8. PubMed ID: 15758755
[TBL] [Abstract][Full Text] [Related]
13. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
14. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
15. Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study.
Dwyer P; Kelleher C; Young J; Haab F; Lheritier K; Ariely R; Ebinger U
Neurourol Urodyn; 2008; 27(6):540-7. PubMed ID: 18663723
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
[TBL] [Abstract][Full Text] [Related]
17. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
[TBL] [Abstract][Full Text] [Related]
18. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
20. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.
Toglia MR; Serels SR; Laramée C; Karram MM; Nandy IM; Andoh M; Seifeldin R; Forero-Schwanhaeuser S
Postgrad Med; 2009 Sep; 121(5):151-8. PubMed ID: 19820284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
